Extracellular matrix integrity: A possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens?

被引:25
作者
Cox, DA [1 ]
Helvering, LM [1 ]
机构
[1] Lilly Res Labs, Muskuloskeletal Res Div, Indianapolis, IN 46285 USA
关键词
estrogen; selective estrogen receptor modulator; uterus; raloxifene; matrix metalloproteinase; extracellular matrix;
D O I
10.1016/j.mce.2005.12.020
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recent gene microarray studies have illustrated heterogeneity in gene expression changes not only between estrogens and selective estrogen receptor modulators (SERMs), but also across different SERM molecules. In ovariectomized rats, this phenomenon was observed with respect to a number of genes involved in collagen turnover and extracellular matrix (ECM) integrity in the uterus and vaginal tissues. Preliminary mechanistic data suggest that these effects on ECM integrity may have relevance in the context of the effect of estrogens and some SERMs to increase the risk of pelvic organ prolapse and the incidence of urinary incontinence in postmenopausal women. Given the pivotal role of ECM integrity and collagen turnover in other tissues and disease states, these processes may provide a fruitful target for future research into the mechanisms for the heterogeneous pharmacology of estrogens and SERMs across different cell types and target tissues. (c) 2005 Elsevier Ireland Ltd. All rights reserved,
引用
收藏
页码:53 / 59
页数:7
相关论文
共 58 条
[1]   Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells [J].
Abidi, SMA ;
Howard, EW ;
Dmytryk, JJ ;
Pento, JT .
CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (04) :432-439
[2]  
[Anonymous], 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001405
[3]   Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes [J].
Ardans, JA ;
Blum, A ;
Mangan, PR ;
Wientroub, S ;
Cannon, RO ;
Wahl, LM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (08) :1265-1268
[4]   Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women [J].
Blum, A ;
Schenke, WH ;
Hathaway, L ;
Mincemoyer, R ;
Csako, G ;
Waclawiw, MA ;
Cannon, RO .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (08) :892-+
[5]   Effects of raloxifene hydrochloride on the endometrium of postmenopausal women [J].
Boss, SM ;
Huster, WJ ;
Neild, JA ;
Glant, MD ;
Eisenhut, CC ;
Draper, MW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (06) :1458-1464
[6]   Collagen metabolism and turnover in women with stress urinary incontience and pelvic prolapse [J].
Chen, BH ;
Wen, Y ;
Li, H ;
Polan, ML .
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2002, 13 (02) :80-87
[7]   Endometrial pathologies associated with postmenopausal tamoxifen treatment [J].
Cohen, I .
GYNECOLOGIC ONCOLOGY, 2004, 94 (02) :256-266
[8]   The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197
[9]   Paraurethral connective tissue in stress-incontinent women after menopause [J].
Falconer, C ;
Ekman-Ordeberg, G ;
Blomgren, B ;
Johansson, O ;
Ulmsten, UF ;
Westergren-Thorsson, G ;
Malmstrom, A .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (01) :95-100
[10]   Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial [J].
Fisher, B ;
Dignam, J ;
Bryant, J ;
Wolmark, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :684-690